An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

PHASE3TerminatedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

March 14, 2019

Primary Completion Date

October 26, 2020

Study Completion Date

October 26, 2020

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Edasalonexent

100 mg/kg/day

Trial Locations (23)

3052

Royal Children's Hospital, Parkville

19104

Children's Hospital of Philadelphia, Philadelphia

20246

University of Hamburg, Hamburg

21205

Kennedy Krieger Institute, Baltimore

21287

Johns Hopkins School of Medicine, Baltimore

30318

Rare Disease Research, LLC, Atlanta

37212

Vanderbilt University Medical Center, Nashville

41685

Queen Silvia Children's Hospital, Gothenburg

48109

University of Michigan, Ann Arbor

52242

University of Iowa Children's Hospital, Iowa City

66205

University of Kansas Medical Center, Fairway

76104

Cook Children's Medical Center, Fort Worth

78229

University of Texas Health Science Center at San Antonio, San Antonio

80337

University of Munich, Munich

84112

University of Utah, Salt Lake City

89145

Las Vegas Clinic, Las Vegas

95817

UC Davis, Sacramento

97239

Shriners Hospital for Children, Portland

02115

Boston Children's Hospital, Boston

K1H 8L1

Children's Hospital of Eastern Ontario, Ottawa

BS2 8AE

Bristol Children's Hospital, Bristol

WC1N 3JH

Great Ormond Street Hospital (GOSH), London

M13 9WL

Royal Manchester Children's Hospital, Manchester

Sponsors
All Listed Sponsors
lead

Catabasis Pharmaceuticals

INDUSTRY

NCT03917719 - An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter